Archives of gynecology

, Volume 240, Issue 4, pp 217–223 | Cite as

Liver structure and function during long-term treatment with cyproterone acetate

  • E. Kaiser
  • H. S. Gruner


Animal experiments and clinical observations have raised the question of liver function in patients on long-term, high-dose administration of sex steroids. The effective treatment of androgenisation demands the prolonged administration of the antiandrogen cyproterone acetate (CPA), which is also a highly effective progestogen. Biochemical tests of liver function and ultrasonographic examinations were performed in 77 women who had been treated with CPA given in the reverse sequential scheme — 100 mg CPA/day from the 1st–10th day combined with 2 mg CPA + 0.05 mg ethinylestradiol/day from the 1st-21st day of each treatment cycle — for 3 to 11 years. No disturbances of the liver structure or function were found.

Key words

Androgenisation Cyproterone acetate Liver function Steroids Liver neoplasm 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brinkmann AO, Lindh LM, Breedveld DI, Mulder E, van der Molen HJ (1983) Cyproterone acetate prevents translocation of the androgen receptor in the rat prostate. Mol Cell Endocrinol 32:117–129PubMedGoogle Scholar
  2. Bruchovsky N (1980) Molecular action of androgens and antiandrogens. In: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (eds) Androgenization in women. Excerpta Medica, Amsterdam Oxford Princeton, pp 7–20Google Scholar
  3. Carrasco D, Pallardo L, Prieto M, Moll JL, Cruz JM, Berenguer J (1984) Hepatic adenomata and androgen treatment. Ann Intern Med 100:316Google Scholar
  4. Committee on Safety of Medicines (1972) Carcinogenicity tests of oral contraceptives. Her Majesty's Stationery Office, London, pp 1–23Google Scholar
  5. Dawber RPR, Sonnex T, Ralfs I (1982) Oral antiandrogen treatment of common baldness in women. Br J Dermatol 107:20Google Scholar
  6. Foss GL, Simpson SL (1959) Oral methyltestosterone and jaundice. Br Med J 5117: 259–263Google Scholar
  7. Garner PR, Poznanski N (1984) Treatment of severe hirsutism resulting from hyperandrogenism with the reverse sequential cyproterone acetate regimen. J Reprod Med 29:232–236PubMedGoogle Scholar
  8. Hammerstein J, Cupceancu B (1969) Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch Med Wochenschr 94:829–834PubMedGoogle Scholar
  9. Hammerstein JK (1977) Stellungnahme zur Entstehung von Lebertumoren unter dem Einfluß von Steroiden. Mitteilungsblatt Endokrinologie-Information 1:58Google Scholar
  10. Hammerstein J, Moltz L, Schwartz U (1983) Antiandrogens in the treatment of acne and hirsutism. J Steroid Biochem 19:591–597PubMedGoogle Scholar
  11. Henry O, Cayer D (1954) Jaundice occuring during methyltestosterone therapy. NC Med J 15:499–503Google Scholar
  12. Holdaway IM, Croxson MS, Ibbertson HK, Sheehan A, Knox B, France J (1985) Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta Endocrinol 109:522–529PubMedGoogle Scholar
  13. Lang R, Redmann U (1979) Non-mutagenicity of some sex hormones in the ames salmonella/microsome mutagenicity test. Mutat Res 67:361–365PubMedGoogle Scholar
  14. de Lorimier AA, Gordan GS, Lowe RC, Carbone JV (1965) Methyltestosterone, related steroids, and liver function. Arch Intern Med 116:289–294PubMedGoogle Scholar
  15. Moltz L, Schwartz U, Hammerstein J (1982) Management of cutaneous virilism with cyproterone acetate. In: Jeffcoate SL (ed) Androgens and anti-androgen therapy. Wiley & Sons, Chichester New York Brisbane Toronto Singapore, pp 113–143Google Scholar
  16. Peraino C, Fry RJM, Staffeldt E, Christopher JP (1977) Enhancing effects of phenobarbitone and butylated hydroxytoluene on 2-acetylaminofluorence-induced hepatic tumorigenesis in the rat. Fd Cosmet Toxicol 15:93–96Google Scholar
  17. Rabe T, Runnebaum B (1982) Kontrazeption. Methoden, Indikation, Kontraindikation. Springer, Berlin Heidelberg New York, pp 67–74Google Scholar
  18. Saheb F (1980) Absence of peliosis hepatis in patients receiving testosterone enanthate. Hepatogastroenterology 27:432–434PubMedGoogle Scholar
  19. Schindler AE, Mangold K, Friedrich E, Keller E, Göser R (1978) Therapy of androgenetic symptomatology with cyproterone acetate and ethinyl estradiol. Arch Gynecol 225:103–107Google Scholar
  20. Schulte-Hermann R (1974) Induction of liver growth by xenobiotic compounds and other stimuli. CRC Crit Rev Toxicol 3:97–158PubMedGoogle Scholar
  21. Schulte-Hermann R, Schuppler J, Ohde G, Timmermann-Trosiener I (1982) Effect of tumor promoters on proliferation of putative preneoplastic cells in rat liver. In: Hecker E, Kunz W (eds) Carcinogenesis. Raven Press, New York, vol 7:99–104Google Scholar
  22. Schulte-Hermann R, Timmermann-Trosiener I, Schuppler J (1983) Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Res 43:839–844PubMedGoogle Scholar
  23. Schuppler J, Günzel P (1979) Liver tumors and steroid hormones in rats and mice. Arch Toxicol [Suppl] 2:181–195Google Scholar
  24. Schuppler J, Dammé J, Schulte-Hermann R (1983) Assay of some endogenous and synthetic sex steroids for tumor-initiating activity in rat liver using the Solt-Farber system. Carcinogenesis 4:239–241PubMedGoogle Scholar
  25. Spech H-J (1985) Leber und orale Kontrazeptiva. Med Klin 80:227–232Google Scholar
  26. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM (1977) Liver damage from long-term methyltestosterone. Lancet 8032:261–263Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • E. Kaiser
    • 1
  • H. S. Gruner
    • 2
  1. 1.Fachbereich Gynäkologie/Gynäkologische EndokrinologieStiftung Deutsche Klinik für Diagnostik Wiesbaden GmbHWiesbadenFederal Republic of Germany
  2. 2.Fachbereich GastroenterologieStiftung Deutsche Klinik für Diagnostik Wiesbaden GmbHWiesbadenFederal Republic of Germany

Personalised recommendations